Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 2:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 343 matching trials from the live ClinicalTrials.gov search.
Filters: "levodopa" Clear all
Completed No phase listed Observational

ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects

NCT00936676
View directory record Official record
Conditions
Parkinson's Disease
Interventions
rasagiline mesylate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
Not listed
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
37
States / cities
Birmingham, Alabama • Tucson, Arizona • Irvine, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Oct 9, 2026, 2:56 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Sustained Release Oral Formulation for Treatment of Parkinson's Disease

NCT05471609
View directory record Official record
Conditions
Healthy Volunteers
Interventions
levodopa/carbidopa oral formulation A, levodopa/carbidopa oral formulation B
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 9, 2026, 2:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Levodopa Response and Gut Microbiome in Patients With Parkinson's Disease

NCT04956939
View directory record Official record
Conditions
Parkinson Disease
Interventions
Low dose levodopa, High dose levodopa
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
40 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Oct 9, 2026, 2:56 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Action Regulation Behavioral

NCT06489483
View directory record Official record
Conditions
Parkinson Disease
Interventions
Action Regulation Movement Task
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 9, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease

NCT01096186
View directory record Official record
Conditions
Parkinson's Disease
Interventions
IPX066 95 mg, IPX066 145 mg, IPX066 195 mg, IPX066 245 mg
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 9, 2026, 2:56 PM EDT
Completed Phase 3 Interventional

Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's

NCT00363727
View directory record Official record
Conditions
Parkinson's Disease, Parkinson Disease, Dyskinesias
Interventions
ropinirole controlled-release (REQUIP CR) for RLS
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 70 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
69
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 9, 2026, 2:56 PM EDT
Completed Not applicable Interventional Results available

Computational Modeling of 60 Hz Subthalamic Nucleus Deep Brain Stimulation for Gait Disorder in Parkinson's Disease

NCT04184791
View directory record Official record
Conditions
Parkinson Disease
Interventions
Deep Brain Stimulation
Device
Lead sponsor
Northwell Health
Other
Eligibility
21 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 9, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease

NCT02542696
View directory record Official record
Conditions
Parkinson Disease
Interventions
APL-130277
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 9, 2026, 2:56 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease

NCT02726386
View directory record Official record
Conditions
Parkinson's Disease
Interventions
ND0612
Drug
Lead sponsor
NeuroDerm Ltd.
Industry
Eligibility
30 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 9, 2026, 2:56 PM EDT
Completed Early Phase 1 Interventional

Improving Walking Automaticity in Parkinson's Disease: Levodopa or Donepezil

NCT03599726
View directory record Official record
Conditions
Parkinson Disease
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
50 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Oct 9, 2026, 2:56 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.

NCT03051607
View directory record Official record
Conditions
Idiopathic Parkinson Disease
Interventions
Tozadenant
Drug
Lead sponsor
Biotie Therapies Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
31
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 3, 2019 · Synced Oct 9, 2026, 2:56 PM EDT
Recruiting Not applicable Interventional

Deep Brain Stimulation Therapy in Movement Disorders

NCT02119611
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Deep Brain Stimulation management
Device
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 9, 2026, 2:56 PM EDT
Terminated Not applicable Interventional Results available

Evaluation of Using Vibrotactile Coordinated Reset for Management of Parkinson's Disease

NCT03857867
View directory record Official record
Conditions
Parkinson Disease
Interventions
Tactile Stimulation Glove
Device
Lead sponsor
Peter Tass, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Oct 9, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease

NCT01968031
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
Istradefylline 40 mg, Istradefylline 20 mg, Placebo
Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
30 Years and older
Enrollment
613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
41
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 9, 2026, 2:56 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.

NCT02153645
View directory record Official record
Conditions
Parkinson's Disease, Levodopa Induced Dyskinesias (LID)
Interventions
240mg Amantadine HCl ER tablets, Placebo tablets, 320mg Amantadine HCl ER tablets
Drug
Lead sponsor
Adamas Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
26
States / cities
Tucson, Arizona • Fountain Valley, California • Irvine, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Oct 9, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients

NCT00479401
View directory record Official record
Conditions
Early Parkinson Disease (Early PD)
Interventions
Pramipexol Extended Release, Pramipexol Immediate Release, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
30 Years and older
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
16
States / cities
Gilbert, Arizona • Sun City, Arizona • La Jolla, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Oct 9, 2026, 2:56 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia

NCT04435431
View directory record Official record
Conditions
Parkinson Disease
Interventions
Mesdopetam, Placebo
Drug
Lead sponsor
Integrative Research Laboratories AB
Industry
Eligibility
30 Years to 79 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
14
States / cities
Scottsdale, Arizona • Long Beach, California • Palo Alto, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 9, 2026, 2:56 PM EDT
Suspended Early Phase 1 Interventional Accepts healthy volunteers

Changes in Glutamatergic Neurotransmission of Severe TBI Patients

NCT04244058
View directory record Official record
Conditions
Disorder of Consciousness, Traumatic Brain Injury
Interventions
Amantadine + L-DOPA, NMDA blocker
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2022 · Synced Oct 9, 2026, 2:56 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

EMG Modules as a Novel Biomarker of Basal Ganglia Plasticity in Parkinson's Disease

NCT02896816
View directory record Official record
Conditions
Parkinson
Interventions
Surface EMG, MRI and PET Scan, Surface EMG
Other
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Oct 9, 2026, 2:56 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dopaminergic Enhancement of Rehabilitation Therapy Early After Stroke

NCT05369533
View directory record Official record
Conditions
Stroke
Interventions
Telerehabilitation, Sinemet Pill, Placebo
Device · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 9, 2026, 2:56 PM EDT
Active, not recruiting No phase listed Observational

Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease

NCT06107426
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
27
States / cities
Birmingham, Alabama • Sun City, Arizona • Palo Alto, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 9, 2026, 2:56 PM EDT
Active, not recruiting Phase 2 Interventional

Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study

NCT05781321
View directory record Official record
Conditions
Glioblastoma
Interventions
Accelerated Hypofractionated Radiation Therapy, Computed Tomography, Fluorodopa F 18, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Temozolomide, Biospecimen Collection
Radiation · Procedure · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
8
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 9, 2026, 2:56 PM EDT
Terminated Not applicable Interventional Results available

Utilization of Target Ranges to Treat Parkinson's Disease With the PKG

NCT03984305
View directory record Official record
Conditions
Parkinson Disease
Interventions
Personal KinetiGraph® (PKG®) Watch, Personal KinetiGraph® (PKG®) Report
Device
Lead sponsor
Global Kinetics Corporation
Industry
Eligibility
46 Years to 83 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
17
States / cities
Fayetteville, Arkansas • Little Rock, Arkansas • Menlo Park, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 9, 2026, 2:56 PM EDT
Completed Early Phase 1 Interventional

A Targeted Amino Acid Supplement for People With Parkinson's Disease

NCT06954662
View directory record Official record
Conditions
Parkinson Disease, Idiopathic
Interventions
Amino acid supplement, Whey Protein Supplement, Isonitrogenous Placebo Supplement
Drug · Dietary Supplement
Lead sponsor
UConn Health
Other
Eligibility
55 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 9, 2026, 2:56 PM EDT